Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells

Anti-Cancer Drugs

Volumn 24, Issue 8, 2013, Pages 810-817

  Long, Qing Zhi ^a   Zhou, Ming ^b   Liu, Xiao Gang ^c   Du, Yue Feng ^a   Fan, Jin Hai ^a   Li, Xiang ^a   He, Da Lin ^a  

^a First Affiliated Hospital   (China)

^b Ear Institute   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

CCN1; integrin avb3; P glycoprotein; PI3K Akt; renal cell carcinoma; vinblastine resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYSTEINE RICH PROTEIN 61; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; VINBLASTINE; VITRONECTIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; COLONY FORMATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE-RICH PROTEIN 61; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHAVBETA3; KIDNEY NEOPLASMS; P-GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; VINBLASTINE;

EID: 84881040306     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328363046d     Document Type: Article

References (32)

1. Morais C, Gobe G, Johnson DW, Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011; 43:1537-1549.
2. Vasko R, Mueller GA, von Jaschke AK, Asif AR, Dihazi H. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis. Eur J Pharmacol 2011; 670:50-57.
3. Ferguson RE, Jackson SM, Stanley AJ, Joyce AD, Harnden P, Morrison EE, et al. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 2005; 115:155-163.
4. Gamelin E, Mertins SD, Regis JT, Mickley L, Abati A, Worrell RA, et al. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol 1999; 162:217-224.
5. Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K. Significance of P-glycoprotein, P53, and survivin expression in renal cell carcinoma. Int J Cancer 2009; 115:155-163.
6. Yu DS, Sun GH, Ma CP, Chang SY. Cocktail modulator mixtures for overcoming multidrug resistance in renal cell carcinoma. Urology 1999; 54:377-381.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738.
8. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
9. Hodkinson P, Sethi T. Extracellular matrix-mediated drug resistance. In: Mehta K, Kapil A, Siddik ZH, Zahid H, editors. Drug resistance in cancer cells. USA: Springer; 2009. pp. 115-135.
10. Elliott T, Sethi T. Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2002; 2:449-459.
11. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119:4803-4810.
12. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41:771-783.
13. Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011; 68:3149-3163.
14. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-687.
15. Zhang Y, Wang H. Integrin signalling and function in immune cells. Immunology 2012; 135:268-275.
16. Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R. A novel CYR61-triggered 'CYR61-avb3 integrin loop'regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2004; 24:761-779.
17. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007; 100:1337-1345.
18. Asakura E, Nakayama H, Sugie M, Lan Zhao Y, Nadai M, Kitaichi K, et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 2004; 484:333-339.
19. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63:1515-1519.
20. You JJ, Yang CH, Chen MS, Yang CM. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50:3447-3455.
21. Chen GK, Durán GE, Mangili A, Beketic-Oreskovic L, Sikic B. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer 2000; 83:892-898.
22. Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One 2012; 7:e46214.
23. Franzen CA, Chen CC, Todorović V, Juric V, Monzon RI, Lau LF. Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 2009; 7:1045-1055.
24. Yoshida Y, Togi K, Matsumae H, Nakashima Y, Kojima Y, Yamamoto H, et al. CCN1 protects cardiac myocytes from oxidative stress via b1 integrin/Akt pathway. Biochem Biophys Res Commun 2007; 355:611-618.
25. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 2009; 9:6.
26. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003; 3:15.
27. Nguyen N, Kuliopulos A, Graham RA, Covic L. Tumor-derived Cyr61 (CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006; 66:2658-2665.
28. Chintalapudi MR, Markiewicz M, Kose N, Dammai V, Champion KJ, Hoda RS, et al. Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis 2008; 29:696-703.
29. Lupu R. Interaction between Cry61 and avbeta3 in breast cancer: role in texan resistance. DTIC document. 2007; Available at: http://oai.dtic.mil/oai/ oai?verb=getRecord&metadataPrefix=html&identifier=ADA478662 [accessed 17 August 2007].
30. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004; 279:24015-24023.
31. Vellon L, Menendez JA, Liu H, Lupu R. Up-regulation of aVb3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation 2007; 75: 819-830.
32. Jin Y, Kim HP, Ifedigbo E, Lau LF, Choi A. Cyr61 protects against hyperoxia-induced cell death via Akt pathway in pulmonary epithelial cells. Am J Respir Cell Mol Biol 2005; 33:297-302.